These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19387776)

  • 1. Estrogen receptor-beta status influences clinical outcome of triple-negative breast cancer.
    Sakamoto G; Honma N
    Breast Cancer; 2009; 16(4):281-2. PubMed ID: 19387776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-negative breast cancer.
    Oncology (Williston Park); 2010 Oct; 24(10 Suppl):40a. PubMed ID: 21275325
    [No Abstract]   [Full Text] [Related]  

  • 3. From the guest editor: Triple-negative breast cancer.
    Hudis CA
    Cancer J; 2010; 16(1):10-1. PubMed ID: 20164684
    [No Abstract]   [Full Text] [Related]  

  • 4. Triple-negative breast cancer and brain metastases.
    Sait B; Cinar E; Altundag K
    Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):84. PubMed ID: 19751969
    [No Abstract]   [Full Text] [Related]  

  • 5. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are triple-negative and basal-like breast cancer synonymous?
    Rakha E; Ellis I; Reis-Filho J
    Clin Cancer Res; 2008 Jan; 14(2):618; author reply 618-9. PubMed ID: 18223240
    [No Abstract]   [Full Text] [Related]  

  • 7. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.
    Bosch A; Eroles P; Zaragoza R; Viña JR; Lluch A
    Cancer Treat Rev; 2010 May; 36(3):206-15. PubMed ID: 20060649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches for triple-negative breast cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):916, 931, 935. PubMed ID: 23175999
    [No Abstract]   [Full Text] [Related]  

  • 11. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.
    Voduc D; Nielsen TO
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S171-8. PubMed ID: 19158038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.
    Neven P; Pochet N; Drijkoningen M; Amant F; De Smet F; Paridaens R; Christiaens MR; Vergote I
    J Clin Oncol; 2006 Jun; 24(16):2595; author reply 2595-7. PubMed ID: 16735717
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
    Broom RJ; Tang PA; Simmons C; Bordeleau L; Mulligan AM; O'Malley FP; Miller N; Andrulis IL; Brenner DM; Clemons MJ
    Anticancer Res; 2009 May; 29(5):1557-62. PubMed ID: 19443366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer in focus: treatment options for triple-negative metastatic breast cancer.
    O'Shaughnessy JA
    Clin Adv Hematol Oncol; 2012 Jan; 10(1):43-5. PubMed ID: 22398807
    [No Abstract]   [Full Text] [Related]  

  • 16. Triple negative breast cancer: breast cancer research in evolution.
    Eng-Wong J; Hunsberger S; Zujewski JA
    Breast Dis; 2010; 32(1-2):1-4. PubMed ID: 21778576
    [No Abstract]   [Full Text] [Related]  

  • 17. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and significanc of ERbeta and HER2 in breast cancer].
    Yang SE; Li X
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):767-8. PubMed ID: 18396690
    [No Abstract]   [Full Text] [Related]  

  • 19. The sensitivity and specificity of estrogen receptor, progesterone receptor and HER-2 staining in core biopsies of invasive breast carcinomas.
    Frederik P; Cecile C; Tjalma WA
    Breast J; 2007; 13(4):436-7. PubMed ID: 17593058
    [No Abstract]   [Full Text] [Related]  

  • 20. [How to optimize the clinical therapeutic protocol for triple-positive breast cancer].
    Wang N; Wang YJ
    Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):241-3. PubMed ID: 20510070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.